Company name change and redomiciliation to Switzerland.
This strategic shift signifies BeiGene's evolution into a global entity, BeOne Medicines, with a new corporate structure and domicile. The move to Switzerland, a hub for life sciences, could streamline international operations and access to capital. While the primary focus is global, this restructuring impacts its APAC operations by aligning them under a new international framework and potentially influencing future investment and strategic partnerships within the region.
The rebranding and redomiciliation to Switzerland create a new global corporate identity for BeiGene. This impacts its APAC operations by integrating them into a unified international strategy, potentially influencing regional investment, partnerships, and market access initiatives under the BeOne Medicines umbrella.
百济神州美国子公司已于2025年3月17日正式更名为BeOne Medicines USA, Inc.。此次更名以及计划迁往瑞士的举措尚待股东批准。公司表示，新名称体现了其致力于开发创新药物并与全球合作以帮助癌症患者的承诺。
登录后可保存信号笔记。
登录